References
Committee for Medicinal Products for Human Use (2011) Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. EMA/759784/2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/01/WC500100710.pdf. Accessed 17 May 2011
Garattini S, Bertele’ V (2007) Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 370(9602):1875–1877. doi:10.1016/S0140-6736(07)61604-3
World Medical Association (1964–2008) (2008) The Declaration of Helsinki. Available at: http://www.wma.net/en/30publications/10policies/b3/. Accessed 18 July 2011
DHHS Food and Drug Administration. 21 CFR part 312 (2008) Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule 28 April 2008, effective, October 27 2008. Available at: http://www.regulations.gov/fdmspublic/component/main?main=DocumentDetail&o=0900006480537f08. Accessed 18 July 2011
Barbui C, Cipriani A, Lintas C, Bertele’ V, Garattini S (2007) CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology (Berl) 190(2):265–268. doi:10.1007/s00213-006-0629-3
Garattini S, Bertele’ V (2002) Efficacy, safety, and cost of new anticancer drugs. Br Med J 325(7358):269–271
Joppi R, Bertele’ V, Garattini S (2005) Disappointing biotech. Br Med J 331(7521):895–897. doi:10.1136/bmj.331.7521.895
Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, Vaccheri A, Montanaro N (2006) An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol 62(5):610–616. doi:10.1111/j.1365-2125.2006.02700.x
Hrobjartsson A, Gotzsche PC (2010) Placebo interventions for all clinical conditions. Cochrane Database Syst Rev (1): CD003974. doi:10.1002/14651858.CD003974.pub3
Acknowledgments
We thank Judith Baggott for editing. This study was supported by internal institutional funds from the Mario Negri Institute and the Copenhagen Trial Unit.
Conflict of interests
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bertele’, V., Banzi, R., Gluud, C. et al. EMA’s reflection on placebo does not reflect patients’ interests. Eur J Clin Pharmacol 68, 877–879 (2012). https://doi.org/10.1007/s00228-011-1175-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1175-4